Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.43 |
| ▸ | TNNC1 | P63316 | 6/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.43 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | CERS2 | Q96G23 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14593328 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2S1PR1TNNC1S1PR3SGPL1 | |
| SCHEMBL14593387 | 0.90 | S1PR1 (0.41) | SMN1; SMN2S1PR1TNNC1S1PR3SGPL1 | |
| SCHEMBL14593245 | 0.82 | S1PR1 (0.51) | S1PR1TNNC1S1PR3SGPL1S1PR4 | |
| SCHEMBL5564657 | 0.81 | S1PR1 (0.55) | SMN1; SMN2S1PR1TNNC1S1PR3SGPL1 | |
| SCHEMBL11927165 | 0.81 | S1PR1 (0.55) | SMN1; SMN2S1PR1TNNC1S1PR3SGPL1 | |
| SCHEMBL6275322 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2S1PR1 | |
| SCHEMBL13215225 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2S1PR1 | |
| SCHEMBL16202061 | 0.72 | SMN1; SMN2 (0.54) | SMN1; SMN2S1PR1 | |
| SCHEMBL27904591 | 0.72 | S1PR1 (0.57) | S1PR1TNNC1S1PR3SGPL1S1PR4 | |
| SCHEMBL5559723 | 0.71 | S1PR1 (0.67) | S1PR1S1PR3S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511473-B1 | BIS-AROMATIC ALKANOLS | NOVARTIS AG (CH) | 2013-04-17 | — | — | EP | disclosed |
| US-7169817-B2 | Bis-aromatic alkanols | IRM LLC (BM) | 2007-01-30 | — | — | US | disclosed |
| US-20040048857-A1 | Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. | IRM LLC (BM) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048857-A1 | Treatment and/or prevention of diseases or disorders mediated by lymphocyte interactions. | CD4, HLA-DRB1, MALT1 | SMN1; SMN2 1231/4885S1PR1 1541/4885TNNC1 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.